Literature DB >> 32090357

Hemostatic Alterations in Patients With Cirrhosis: From Primary Hemostasis to Fibrinolysis.

Maxime G Zermatten1, Montserrat Fraga2, Darius Moradpour2, Debora Bertaggia Calderara1, Alessandro Aliotta1, Guido Stirnimann3, Andrea De Gottardi3,4, Lorenzo Alberio1.   

Abstract

In the setting of liver cirrhosis (LC), profound hemostatic changes occur, which affect primary hemostasis, coagulation, and fibrinolysis. They involve prohemorrhagic and prothrombotic alterations at each of these steps. Patients with cirrhosis exhibit multifactorial thrombocytopenia and in vitro thrombocytopathy, counterbalanced by increased von Willebrand factor. The resultant shift is difficult to assess, but overall these changes probably result in a rebalanced primary hemostasis. Concerning coagulation, the reduced activity of coagulation factors is counterbalanced by an increase in factor VIII (produced by liver sinusoidal endothelial cells), a decrease of the natural anticoagulants, and complex changes, including changes in circulating microparticles, cell-free DNA, and neutrophil extracellular traps. Overall, these alterations result in a procoagulant state. As for fibrinolysis, increased tissue-type and urokinase-type plasminogen activators, a relatively decreased plasminogen activator inhibitor 1, and decreased levels of thrombin-activatable fibrinolysis inhibitor and α2-antiplasmin are counterbalanced by decreased plasminogen and a decreased fibrin clot permeability. Whether and how these changes shift fibrinolysis remains to be determined. Overall, the current consensus is that in patients with cirrhosis, the hemostasis is shifted toward a procoagulant state. We review the published evidence for the concept of LC as a prothrombotic state, discuss discordant data, and highlight the impact of the underlying cause of LC on the resultant imbalance.
© 2020 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2020        PMID: 32090357     DOI: 10.1002/hep.31201

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  13 in total

Review 1.  Management of acute renal replacement therapy in critically ill cirrhotic patients.

Authors:  Jimena Del Risco-Zevallos; Alicia Molina Andújar; Gastón Piñeiro; Enric Reverter; Néstor David Toapanta; Miquel Sanz; Miquel Blasco; Javier Fernández; Esteban Poch
Journal:  Clin Kidney J       Date:  2022-01-28

2.  Acute Kidney Injury in Decompensated Cirrhosis Is Associated With Both Hypo-coagulable and Hyper-coagulable Features.

Authors:  Alberto Zanetto; Henry M Rinder; Elena Campello; Graziella Saggiorato; Yanhong Deng; Maria Ciarleglio; Francis P Wilson; Marco Senzolo; Sabrina Gavasso; Cristiana Bulato; Paolo Simioni; Guadalupe Garcia-Tsao
Journal:  Hepatology       Date:  2020-10       Impact factor: 17.425

Review 3.  Consensus Statement on Hemostatic Management, Anticoagulation, and Antiplatelet Therapy in Liver Transplantation.

Authors:  Eva Montalvá; Manuel Rodríguez-Perálvarez; Annabel Blasi; Santiago Bonanad; Olga Gavín; Loreto Hierro; Laura Lladó; Elba Llop; Juan Carlos Pozo-Laderas; Jordi Colmenero
Journal:  Transplantation       Date:  2022-01-04       Impact factor: 5.385

4.  Biomarkers of liver dysfunction correlate with a prothrombotic and not with a prohaemorrhagic profile in patients with cirrhosis.

Authors:  Maxime G Zermatten; Montserrat Fraga; Debora Bertaggia Calderara; Alessandro Aliotta; Darius Moradpour; Lorenzo Alberio
Journal:  JHEP Rep       Date:  2020-05-11

5.  Reduced Clot Stability by Thromboelastography as a Potential Indicator of Procedure-Related Bleeding in Decompensated Cirrhosis.

Authors:  Alberto Zanetto; Henry M Rinder; Marco Senzolo; Paolo Simioni; Guadalupe Garcia-Tsao
Journal:  Hepatol Commun       Date:  2020-12-12

6.  Impact of Platelet Count on Perioperative Bleeding in Patients With Cirrhosis Undergoing Surgical Treatments of Liver Cancer.

Authors:  Vincenzo Ronca; Matteo Barabino; Roberto Santambrogio; Enrico Opocher; James Hodson; Emanuela Bertolini; Simone Birocchi; Gaetano Piccolo; PierMaria Battezzati; Marco Cattaneo; Gian Marco Podda
Journal:  Hepatol Commun       Date:  2021-10-30

7.  More Pronounced Hypercoagulable State and Hypofibrinolysis in Patients With Cirrhosis With Versus Without HCC.

Authors:  Marco Senzolo; Paolo Simioni; Alberto Zanetto; Elena Campello; Cristiana Bulato; Sabrina Gavasso; Graziella Saggiorato; Sarah Shalaby; Luca Spiezia; Umberto Cillo; Fabio Farinati; Francesco Paolo Russo; Patrizia Burra
Journal:  Hepatol Commun       Date:  2021-08-16

Review 8.  The hemostatic and thrombotic complications of liver disease.

Authors:  Hannah Stowe McMurry; Janice Jou; Joseph Shatzel
Journal:  Eur J Haematol       Date:  2021-07-29       Impact factor: 2.997

9.  Cirrhosis-Associated RAS-Inflammation-Coagulation Axis Anomalies: Parallels to Severe COVID-19.

Authors:  Lukas Hartl; Mathias Jachs; Benedikt Simbrunner; David J M Bauer; Georg Semmler; Daniela Gompelmann; Thomas Szekeres; Peter Quehenberger; Michael Trauner; Mattias Mandorfer; Bernhard Scheiner; Thomas Reiberger
Journal:  J Pers Med       Date:  2021-12-01

10.  Neutrophil extracellular traps in patients with liver cirrhosis and hepatocellular carcinoma.

Authors:  Robin Zenlander; Sebastian Havervall; Maria Magnusson; Jennie Engstrand; Anna Ågren; Charlotte Thålin; Per Stål
Journal:  Sci Rep       Date:  2021-09-09       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.